<DOC>
	<DOCNO>NCT01245543</DOCNO>
	<brief_summary>AC480IV administer monotherapy combination docetaxel patient locally advance metastatic solid tumor standard curative therapy available . It design evaluate safety pharmacokinetic parameter AC480IV monotherapy also combination docetaxel condition study .</brief_summary>
	<brief_title>Safety Study Intravenous ( IV ) AC480 ( AC480IV ) Treat Advanced Solid Tumors</brief_title>
	<detailed_description>A Phase I study determine safety tolerability AC480IV without Docetaxel subject solid tumor .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Male female age ≥18 year 2 . Provide write informed consent 3 . Has histological diagnosis primary solid tumor malignancy meet study criterion 4 . Has measurable disease ( evaluable MTD expansion cohort ) via compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan without nonmeasurable tumor ( lesion previously irradiate area eligible consider measurable disease long objective evidence progression lesion prior enrollment ) 5 . Less 4 prior systemic cancer therapy ( exception hormonal agent ) , include experimental agent , prior HERfamily TKI therapy , prior docetaxel taxane therapy ; limit number prior therapy Part 1 6 . Women childbearing potential ( WOCBP ) must use adequate method contraception . 7 . WOCBP must negative serum urine pregnancy test ( sensitivity ≤ 25IU human chorionic gonadotropin [ hCG ] /L ) within 72 hour prior start study drug administration 8 . Has ECOG performance status 0 1 9 . Has life expectancy &gt; 3 month 10 . Has adequate organ function determine laboratory test 1 . Patient currently receive receive within last month prior Cycle 1 Day 1 ( 6 week nitrosoureas , mitomycinC , liposomal doxorubicin ) chemotherapeutic , hormonal , investigational anticancer agent exception gonadal suppression agent bisphosphonates osteoporosis skeletal metastasis may continue study 2 . Patient receive chemotherapeutic , hormonal , investigational anti cancer agent outside timeframe describe thus would allow study , toxicity unresolved ( i.e. , toxicity resolve Grade ≤ 1 deem irreversible ) 3 . Current anticipate need drug know cytochrome P450 isozyme CYP3A4 CYP2C8 inducer inhibitor ; exception oral glucocorticoid , require premedication docetaxel 4 . Patient receive previous treatment oral AC480 5 . Patient use herbal dietary supplement may interact CYP3A4 6 . Patient receive radiation therapy major surgery within one month Cycle 1 Day 1 7 . Patient evidence clinically unstable brain metastasis ( control stable brain metastasis must previously treat asymptomatic ) 8 . Patient uncontrolled significant cardiovascular disease , include : A myocardial infarction within 6 month prior study entry ; Uncontrolled angina within 6 month prior study entry ; History congestive heart failure ( CHF ) New York Heart Association ( NYHA ) class 3 4 ; LVEF ≤50 % ( ≥ institutional low limit normal ) ; Heart rate &lt; 50 beat per minute ; Diagnosed suspect congenital long QT syndrome ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de Pointes [ TdP ] ) ; Prolonged correct interval Q wave T wave ( QTc ) Fridericia 's correction factor ( QTcF ) interval preentry ECG ≥450 m ( average 3 ECG reading do triplicate ) ; Any history second third degree heart block ; Uncontrolled hypertension ; Obligate need cardiac pacemaker ; Complete leave bundle branch block ; Atrial fibrillation ; Abnormal baseline TroponinI . 9 . Patient use drug ( medical condition ) generally accept risk cause torsades de pointes ( TdP ) patient discontinue medication must washout period least 5 day 5 halflives drug ( whichever great ) prior first dose AC480IV 10 . Patient need anticoagulation therapy except lowdose heparin lowdose coumadin maintenance patency central venous access prevention deep vein thrombosis ( DVT ) 11 . Women pregnant breastfeed 12 . Male female patient sexually active unwilling take contraceptive measure duration treatment 3 month follow discontinuation AC480IV 13 . Patient serious uncontrolled concurrent medical illness include limited ongoing active infection , `` currently active '' second malignancy nonmelanoma skin cancer 14 . Patient psychiatric illness social situation would limit compliance treatment adequate inform consent 15 . Patient preexist peripheral neuropathy Grade &gt; 1 16 . Patient prior hypersensitivity reaction intolerance docetaxel drug formulate polysorbate 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>